Koyfin Home > Directory > Health Care > Pieris Pharma > Gross Margin

Pieris Pharma Gross Margin Chart (PIRS)

Pieris Pharma annual/quarterly Gross Margin from 2013 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Pieris Pharma Gross Margin for the quarter ending September 09, 2020 was $-302m a 133.09% decrease of -402m year over year
  • Pieris Pharma Gross Margin for the last 12 months ending September 09, 2020 was $111m a 10.00% increase of 11m year over year
  • Pieris Pharma Annual Gross Margin for 2019 was $100m a 0.00% decrease of 0m from 2018
  • Pieris Pharma Annual Gross Margin for 2018 was $100m a 0.00% decrease of 0m from 2017
  • Pieris Pharma Annual Gross Margin for 2017 was $100m a 0.00% decrease of 0m from 2016
Other Margins & Efficiency Metrics:
  • Pieris Pharma EBITDA Margin for the quarter ending September 09, 2018 was $-92m a 139.47% decrease of -128m year over year
  • Pieris Pharma Return on Capital % for the quarter ending September 09, 2018 was -36.96 a 645.81% decrease of -238.68 year over year
  • Pieris Pharma Return on Equity % for the quarter ending September 09, 2018 was -46.62 a 899.29% decrease of -419.28 year over year
View Chart On Koyfin

Quarterly PIRS Gross Margin Data

09/2020$-302m
06/2020$-1m
03/2020$4m
12/2019$100m
09/2019$13m
06/2019$-151m
03/2019$-67m
12/2018$100m
09/2018$100m
06/2018$100m

Annual PIRS Gross Margin Data

2019$100m
2018$100m
2017$100m
2016$100m
2015$100m
2014$100m
2013$100m
2012$100m